Seegene and Werfen to Jointly Develop Syndromic qPCR Assays

Seegene, Inc. (Seoul, Korea) has entered into discussions with Werfen (Barcelona, Spain) to expand their ongoing collaboration within the Spanish and Portuguese markets through Seegene's OneSystem Business. Seegene and Werfen have a long-standing relationship, and the extended partnership will enable the co-development of syndromic qPCR assays suited for the healthcare systems of Spain and Portugal at Werfen's OEM Technology Center in Spain. These assays will include those for sexually transmitted infections and drug resistance.

The objective of Seegene's OneSystem Business is to share its syndromic quantitative PCR technologies and its SGDDS (digitalized development system). This system allows researchers, regardless of their experience level, to develop assays. Furthermore, Seegene aims to provide automated manufacturing technologies to create syndromic PCR assays compatible with its standardized OneSystem instruments. Through this partnership, Spain and Portugal will gain the knowledge and technology to develop and manufacture syndromic qPCR assays, thus creating an infrastructure capable of responding swiftly to future pandemics without depending on foreign products and resources.

Seegene's OneSystem Business is pursuing its ultimate goal of creating a world free from all diseases, including cancer and infectious diseases that affect not only humans but all organisms. To fulfill this objective, Seegene is building an open innovation global network where scientists worldwide can collaborate to develop syndromic quantitative PCR assays tailored to local needs. As part of this initiative, Seegene is actively looking for additional partners from other European countries to join its global network and anticipates further agreements to be concluded throughout the year to expedite the expansion of its OneSystem Business.

"We will share our PCR technologies and know-how with any company in any country wishing to develop syndromic quantitative PCR assays," said Dr. Jong-Yoon Chun, CEO of Seegene. "We aspire to develop PCR diagnostic assays for all diseases so that the world free from diseases would come closer."

"We are excited about the possibility of strengthening our partnership with Seegene, and we look forward to developing assays which are tailor-made for Spain and Portugal," said José Luis Zarroca, Chief Operating Officer, OEM at Werfen.

Related Links:
Seegene, Inc. 
Werfen 

Visit expo >

Gold Member

Troponin T QC

Troponin T Quality Control

Automated Blood Typing System
IH-500 NEXT

New

Nuclear Matrix Protein 22 Test

NMP22 Test

New

Urine cfDNA Extraction Kit

CloNext Urine cfDNA Extraction Kit